IJBPAS, August, 2026, 15(8): 3696-3705

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

ERECTILE DYSFUNCTION: A REVIEW

VASANTHA G, KIRANMAI S*AND RAMYA K

Department of Pharmacology, Vignan Institute of Pharmaceutical Technology (A), Duvvada, Visakhapatnam, Andhra Pradesh, India

***Corresponding Author: Mrs Sarvasiddi Kiranmai S: E Mail: sarvasiddikiranmai@gmail.com**

Received 26th June 2025; Revised 10th Aug. 2025; Accepted 12th Nov. 2025; Available online 1st Aug. 2026

https://doi.org/10.31032/IJBPAS/2026/15.8.10373

ABSTRACT

The chronic inability to obtain or sustain an erection strong enough for fulfilling sexual activity is the hallmark of erectile dysfunction (ED), a prevalent male sexual disease. This review provides a comprehensive overview of ED, exploring it etiology, pathophysiology, diagnostic methods, and available treatment options. Both pharmacological and non-pharmacological treatments are discussed, with emphasis on the growing role of novel therapies including low-intensity shockwave therapy and regenerative medicine. Preventive strategies and the importance of early diagnosis are also highlighted. In addition, the review considers current research trends and future directions in the management of ED.

Keywords: Erectile Dysfunction, Prevalance, Pathophysiology, Clinical diagnosis, Life style modifications

INTRODUCTION

Erectile dysfunction (ED) is the inability to regularly or consistently get and/or maintain a penile erection powerful enough for sexual pleasure. Millions of men worldwide suffer from this common ailment, which becomes worse as people age.

According to the Massachusetts Male Aging Study (MMAS), approximately 52% of men aged 40–70 years experience some degree of ED **[1]**. The global prevalence is expected to increase due to rising rates of lifestyle diseases and aging populations. ED is not only a sexual health issue but also a marker for overall health, often

indicating cardiovascular or metabolic disorders. Its impact extends beyond physical health, affecting emotional well-being, relationships, and overall quality of life. Given its multifactorial nature, a comprehensive understanding is essential for effective diagnosis and management.

Etiology and Risk Factors

The causes of ED are broadly classified into organic and psychogenic categories, with many cases involving a combination of both.

Organic Causes

1. Vascular: Atherosclerosis, hypertension, and hyperlipidemia lead to reduced penile blood flow.
2. Neurological: Disorders that interfere with nerve signals include multiple sclerosis, Parkinson's disease, and spinal cord injuries.
3. Hormonal: Hypogonadism (low testosterone levels), hyperprolactinemia, and thyroid disorders affect libido and erection.
4. Medications: Antihypertensives, antidepressants, antipsychotics, and chemotherapy agents may contribute to ED.
5. Psychogenic Causes
   - Performance anxiety
   - Depression
   - Relationship conflicts
   - Stress and fatigue
6. Lifestyle and Other Risk Factors
   - Smoking
   - Alcohol abuse
   - Obesity
   - Sedentary lifestyle
   - Diabetes mellitus
   - Metabolic syndrome
   - Obstructive sleep apnoea
   - Pelvic surgeries and trauma

Pathophysiology and Pathology

A neurovascular event is an erection modulated by hormonal and psychological factors. It involves relaxation of penile smooth muscles, increased blood flow through the cavernosal arteries, and restriction of venous outflow.

Normal Erection Physiology Nitric oxide (NO) is released by nonadrenergic-noncholinergic (NANC) neurons and endothelial cells in response to sexual stimulation.NO activates guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP), leading to smooth muscle relaxation and increased blood flow.

Pathophysiological Disruption

- Endothelial Dysfunction: Reduces NO availability, impairing vasodilation.
- Atherosclerosis: Narrows penile arteries, reducing blood flow. 33. Neuropathy: Common in diabetes; affects nerve signalling **[2-4]**.

- Fibrosis of Corpora Cavernosa: From aging, inflammation, or trauma; impairs veno-occlusion.
- Testosterone Deficiency: Reduces libido and impairs NO production.



Figure 1
(adapted from: https://share.google/images/chrAKllcf5EOwaBbZ)

- Shared Decision Making
- The 2018 AUA Guidelines Statement on ED states that collaborative decision-making is the suggested method for treating ED patients. Using the best available evidence, the doctor uses this technique to educate the patient and his partner about the range of appropriate treatment options that are accessible to them; additional diagnostic tests may be needed or recommended.
- An open discussion about the advantages and disadvantages of testing and therapy ultimately leads to an informed patient choice that is in line with the couple's values and preferences. This is similar to the previous "goal-oriented" approach of prominent urologist Dr. Tom Lue, who recommended that instead of pursuing extensive testing that ultimately has little impact on results, medical professionals focus on realistically discussing therapeutic options with patients to help them choose their own course of treatment **[5]**.
- This method is based on the idea that there is no effective solution for purely psychogenic ED, with the possible exception of psychotherapy; determining the underlying reason is only useful in identifying other possible health problems and comorbidities. In light of this, the emphasis shifts from costly diagnostic testing that won't have a big impact on the outcome to helping patients choose their course of therapy following a thorough discussion of appropriate therapeutic choices. In light of this, patients with ED typically don't need any additional testing, while

certain people might benefit from specialist testing.

Further Testing (Optional)

The following diagnostics for ED patients should all be regarded as optional for a limited number of patients. A simple office screening test for penile neuropathy using skin vibrational threshold sensitivity is called penile biothesiometry. A vibrating probe with a blunt tip is placed on the left and right shafts, along with the glans, as part of the procedure. In order to ascertain their threshold vibrational sensitivity, patients must specify when they initially feel the tip vibrating. After taking five different measurements at each location and averaging the findings, this value is compared to age-based normal criteria **[6]**. It is a sensible, secure, and affordable office test for penile neuropathy, even if it does not directly evaluate the erectile nerves. More specific nerve testing may be performed on patients who test positive.

While men with biological issues will exhibit abnormal nocturnal erectile activity, men with simply psychogenic ED will usually show normal NPT tracings. In NPT investigations, hypogonadism frequently results in a reduction in stiffness while preserving some tumescence. These days, NPT monitoring is hardly ever performed or thought to be required to accurately differentiate between biological and psychogenic erectile dysfunction **[7]**. Determining important psychogenic factors usually requires a thorough and comprehensive sexual and life history.

Although unproven, some have hypothesized that people with aberrant biothesiometry tests may have denervation hypersensitivity, which would make them hypersensitive to intracavernosal injection therapy. In order to differentiate between biological and psychogenic erectile dysfunction, nocturnal tumescence testing (NPT) is useful. The frequency, duration, peak stiffness, and tumescence (changes in circumference) of nocturnal erections are all measured during testing. Nocturnal erections usually happen during REM sleep and necessitate full neurovascular axis activity. An average functioning man experiences three to six erections per night, with a mean duration exceeding thirty minutes, maximal rigidity exceeding seventy percent at the base and tip, and an increase in circumference exceeding three centimeters at the base and two centimeters at the tip. Then, usually over the course of three nights, this process is repeated.

(This also functions as a penile injection therapy clinical trial.) Peak systolic velocities (PSV) are measured after the injection. A reading of less than 25 cm/s indicates arterial insufficiency, but a value greater than 35 cm/s is considered normal. For patients with aberrant pudendal arteriography, a value of less than 25 cm/s

was reported to have 100% sensitivity and 95% specificity. Due to their elevated cardiovascular risk, hypertensive individuals with vasculogenic ED—which is indicated by a markedly decreased cavernosal arterial flow on duplex ultrasound—should be referred for a full cardiac evaluation.

Additionally, cavernous veno-occlusive dysfunction—often referred to by patients as "venous leak"—can be seen on ultrasound; this condition indicates that penile corporal stiffness has failed despite sufficient artery inflow. Rapid detumescence in spite of normal peak systolic and end-diastolic velocities (EDV > 5 cm/s) indicates venous leakage. Veno-occlusive dysfunction can be diagnosed with the help of the vascular resistive index (RI) measurement. Use the formula RI = (PSV-EDV)/PSV to determine RI. Veno-occlusive dysfunction is consistent with a RI < 0.75. This investigation's primary advantages are its non-invasiveness and its precise exclusion of both venous and penile arterial dysfunctions. Erroneous readings can be produced by aberrant anatomy, and the results are very user-dependent. Furthermore, the majority of patients would continue to receive the same information and care.

Erroneous readings can be produced by aberrant anatomy, and the results are very user-dependent. Furthermore, the majority of patients would continue to receive the same information and care.

For a thorough cardiac assessment, refer hypertensive patients with vasculogenic ED who exhibit markedly decreased cavernosal arterial flow on duplex ultrasonography. For patients with a suspected site-specific venous leak, such as those who have experienced pelvic or perineal trauma or who have primary erectile dysfunction (i.e., never been able to attain an erection), use dynamic infusion cavernosometry and cavernosography.

Corrective vascular surgery is typically preceded by these examinations. In order to measure intracavernous pressure and deliver saline concurrently, two needles are inserted into the penis. Veno-occlusive dysfunction is demonstrated by either the abrupt drop in intracavernous pressure following the cessation of the saline infusion or the inability to increase intracavernous pressure to equal the mean systolic blood pressure with the saline infusion.

The location of the veno-occlusive dysfunction is visible on cavernosography.

The penile artery vasculature can be clearly seen using podendal arteriography **[8]**. This test is only used for young patients who have trauma-related erectile dysfunction and may benefit from revascularization surgery. Careful attention is paid to the anatomy of the penile, internal iliac, and

internal pudendal arteries. The possibility of using the inferior epigastric arteries for penile revascularization is also investigated.

Numerous techniques, including peripheral artery tonometry, flow-mediated dilatation, and the penile nitric oxide release test, can be used to assess endothelial cell dysfunction. Additionally, there are other serum indicators, including vascular cell adhesion molecule-1, endothelin 1, C reactive protein, and the presence of endothelial progenitor cells and microparticles. These endothelial cell function assays are now of research relevance solely and have little clinical use.

Diagnosis

Accurate diagnosis involves a comprehensive assessment including history-taking, physical examination, and specific diagnostic tests.

Clinical History

A thorough sexual, medical, and psychosocial history is essential. Tools like the International Index of Erectile Function (IIEF) questionnaire help quantify severity.

Physical Examination Focuses on signs of hormonal imbalances, peripheral vascular disease, and neurological deficits **[9]**.

Laboratory Tests

- Serum testosterone.
- Fasting blood glucose and lipid profile.
- Thyroid function tests.
- Prolactin levels.
- PSA (Prostate-Specific Antigen) for older patients **[10]**.

Specialized Tests

- Nocturnal penile tumescence (NPT).
- Penile Doppler ultrasound.
- Dynamic infusion cavernosometry and cavernosography (DICC).
- Neurological testing (bulbocavernosus reflex, penile biothesiometry) **[11]**.

Treatment Approaches Management of ED should be individualized based on etiology, severity, patient preference, and comorbidities.

Lifestyle Modifications

- Weight loss
- Smoking cessation
- Regular exercise
- Dietary improvements (Mediterranean diet)

Oral Medications

Phosphodiesterase type 5 (PDE5) inhibitors:

Sildenafil, tadalafil, vardenafil, avanafil {Improve erectile response by enhancing the NO-cGMP pathway **[12][13]**

Side effects: headache, flushing, nasal congestion, dyspepsia, back pain [Contraindicated with nitrates]

Hormonal Therapy

- Testosterone replacement therapy in hypogonadal men
- Forms: gels, injections, patches, oral formulations **[14]**
- Requires baseline and follow-up testosterone, hematocrit, and PSA monitoring

Vacuum Erection Devices (VEDs)

- Non-invasive option
- May cause bruising or discomfort
- Effective in patients who prefer non-pharmacologic therapy **[15]**

Intracavernosal Injections

Eg: Alprostadil, papaverine, phentolamine

[High efficacy but potential for priapism, fibrosis **[16]**

Intraurethral Therapy

- Alprostadil suppository (MUSE) **[17]**
- Less effective than injection

Penile Prosthesis Surgery

Types: inflatable, malleable

Reserved for refractory cases

High satisfaction rates

Psychotherapy and Counseling

Particularly effective for psychogenic ED

Involves cognitive behavioral therapy (CBT), couple's therapy **[18][19]**

Emerging Therapies

1) **Low-intensity shockwave therapy (LiSWT):** Promotes angiogenesis and neovascularisation **[20]**
2) **Stem cell therapy and platelet-rich plasma (PRP)**: Regenerative potential; in clinical trials **[21]**
3) **Gene therapy**: Promising but experimental

Prognosis and Outcomes ED is a treatable condition with a generally favourable prognosis, especially when addressed early. Outcomes depend on the underlying cause and adherence to treatment. Psychosocial support enhances recovery and satisfaction. Long-term use of PDE5 inhibitors is safe and effective. Early lifestyle intervention can reverse ED in early stages.

Prevention and Health Education

- Public health strategies and education can reduce the burden of ED
- Promote healthy lifestyle behaviors
- Screen at-risk populations (e.g., diabetic men)
- Encourage open discussions about sexual health
- Address misconceptions and stigma around ED
- Integrate sexual health into primary care

Current Research and Future Directions

1. Research is focused on developing more effective and less invasive treatments.

2. Novel PDE5 inhibitors with fewer side effects
3. Gene therapy targeting endothelial function
4. Regenerative approaches using stem cells and exosomes
5. Role of wearable technology in monitoring sexual health
6. Neurostimulation techniques (e.g., dorsal nerve stimulation)
7. Use of artificial intelligence in diagnosis and treatment planning
8. Future management may include personalized medicine approaches based on genetic and epigenetic markers.

CONCLUSION:

Erectile dysfunction is a multifactorial disorder that reflects broader health concerns. Comprehensive evaluation and individualized treatment can lead to successful outcomes. Advances in research promise innovative therapies that may revolutionize ED management. Clinicians must adopt a holistic approach, addressing both physical and emotional aspects of this condition.

REFERENCES

[1] Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, *et al*. European Association of Urology. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. EurUrol 2010;57:804-10.

[2] Kloner, R. A., & Carson, C. (2017). Erectile dysfunction and cardiovascular risk factors. Urology, 110, 122–129.

[3] Andersson, K.-E. (2011). Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacological Reviews, 63(4), 811–859.

[4] Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. The New England journal of medicine. 1989;320(16):1025-30. Epub 1989/04/20.

[5] Kirby M, Jackson G, Betteridge J, Friedli K. Is erectile dysfunction a marker for cardiovascular disease? International journal of clinical practice. 2001;55(9):614-8. Epub 2002/01/05.

[6] Wylie KR, editor. ABC of sexual health. 3rd ed. Hoboken (NJ): Wiley; 2015.

[7] Rew KT, Heidelbaugh JJ. Erectile dysfunction. Am Fam Physician 201Rew KT, Heidelbaugh JJ.

Erectile dysfunction. Am Fam Physician 2016;94:820-7.

[8] Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319-26.

[9] D. Hatzichristou *et al.* Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med (2010)

[10] Wein AJ, Van Arsdalen KN. Drug-induced male sexual dysfunction. Urol Clin North Am. 1988;15:23-31.

[11] Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assesment of erectile dysfunction. Urology. 1997;49:822-830.

[12] The process of care model for evaluation and treatment of erectile dysfunction. The Process of Care Consensus Panel. International journal of impotence research. 1999;11(2):59-70.

[13] Hatzichristou D, Rosen RC, Derogatis LR, *et al*. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010; 7: 337–48

[14] Kedia GT, Uckert S, Assadi-Pour F, Kuczyk MA, Albrecht K. Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties. Therapeutic advances in urology. 2013;5(1):35-41

[15] Gruenwald I, Appel B, Kitrey ND, Vardi Y. Shockwave treatment of erectile dysfunction. Ther Adv Urol2013;5:95-9. 10.1177/1756287212470696

[16] Belew D, Klaassen Z, Lewis RW: Intracavernosal Injection for the Diagnosis, Evaluation, and Treatment of Erectile Dysfunction: A Review. Sex Med Rev. 2015;3(1):11–23.

[17] Costa P, Potempa AJ: Intraurethral alprostadil for erectile dysfunction: a review of the literature. Drugs. 2012;72(17):2243–54.

[18] Melnik T, Althof S, Atallah AN, Puga ME, Glina S, Riera R. Psychosocial interventions for premature ejaculation. The Cochrane database of systematic reviews. 2011(8):CD008195. Epub 2011/08/13.

[19] Hawton K, Catalan J, Martin P, Fagg J. Long-term outcome of sex therapy. Behaviour research and therapy. 1986;24(6):665-75. Epub 1986/01/01.

[20] Vardi Y, Appel B, Jacob G, *et al*., Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. EurUrol. 2010;58(2): 243–810.

[21] Qiu X, Villalta J, Ferretti L, *et al*.: Effects of intravenous injection of adipose-derived stem cells in a rat model of radiation therapy-induced erectile dysfunction. J Sex Med. 2012;9(7):1834–41.